2024-518797-13-00
CTIS ↗
CNTY-101-151-01
systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic inflammatory myopathy [IIM], and diffuse cutaneous systemic sclerosis [DcSSc]
biotech · Hematological or solid tumor malignancies or autoimmune diseases · Intracerebral Haemorrhage · IPSC
Century Therapeutics
Century Therapeutics trial registry — 11 ClinicalTrials.gov studies with program phase, status, and indication context.
Philadelphia, USA HQ
2018 Founded
104 Employees
Public company Type
IPSC · NYSE Ticker
Company details
- Status
- Public
- HQ
- Philadelphia, USA
- Founded
- 2018
- Employees
- 104
- Programs
- 10
- Drugs
- 9
- Patents
- 39
Century Therapeutics clinical trials
Registry index of 11 ClinicalTrials.gov studies linked to Century Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Century Therapeutics trial registry — 11 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Century Therapeutics.
-
CNTY-LTFU-01 — Phase 1
Clinical update -
CNTY-101-151-01 — Phase 1
Clinical update -
Nicotine gum (C) — Phase 1
Clinical update -
Stromal-vascular fraction — Phase 2
Clinical update -
DAOSiN®/ Placebo & ProvokAmin® Ingestion — Unknown
Clinical update -
CNTY-101 — Phase 1
Clinical update -
Aspirin 75 mg daily — Phase 3
Clinical update -
X-22 Smoking Cessation Product — Phase 2
Clinical update